Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VBMCP vs VBMCP Alternating with High-Dose Cyclophosphamide and Interferon in Multiple Myeloma
NCT00002556Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 1994
- Primary completion
- Jan 2006
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of interferon alfa-2b in multiple myeloma (MM) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Median survival at 1 year, Objective response at 1 year and 3 more. Started Jul 1994; status: completed.
02
Drugs
interferon alfa-2b
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00002556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002556.